Position of nuclear medicine techniques in the diagnostic work-up of neuroendocrine tumors

Quarterly Journal of Nuclear Medicine and Molecular Imaging

Volumn 48, Issue 2, 2004, Pages 150-163

  Bombardieri, E ^a   Seregni, E ^a   Villano, C ^a   Chiti, A ^b   Bajetta, E ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

Author keywords

3 iodobenzylguanidine; Fludeoxyglucose; Neuroendocrine tumors; Nuclear medicine; Octreotide, radionuclide imaging; Positron emission tomography; Radio pharmaceuticals; Receptor imaging

Indexed keywords

(3 IODOBENZYL)GUANIDINE; (3 IODOBENZYL)GUANIDINE I 123; (3 IODOBENZYL)GUANIDINE I 131; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID LANREOTIDE IN 111; 5 HYDROXYTRYPTOPHAN; 6 FLUORODOPAMINE; CARBON 11; CARCINOEMBRYONIC ANTIGEN MONOCLONAL ANTIBODY; CHROMOGRANIN A; DEPREOTIDE TC 99M; DOPA; FLUORODEOXYGLUCOSE F 18; GLUCOSE; IODINE 124; MONOCLONAL ANTIBODY; PENTETREOTIDE; PENTETREOTIDE IN 111; RADIOPHARMACEUTICAL AGENT; RECEPTOR; SOMATOSTATIN DERIVATIVE; SUCCIMER TC 99M; TECHNETIUM 99M; TRACER; UNCLASSIFIED DRUG; VAPREOTIDE TC 99M; VASOACTIVE INTESTINAL POLYPEPTIDE I 123; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR; VASOACTIVE INTESTINAL POLYPEPTIDE TC 99M; DIAGNOSTIC AGENT;

BIOCHEMISTRY; CANCER RADIOTHERAPY; CANCER SCINTISCANNING; CANCER STAGING; CANCER SURGERY; CLINICAL FEATURE; CLINICAL PROTOCOL; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC PROCEDURE; DRUG BINDING; DRUG RESEARCH; DRUG UPTAKE; DRUG USE; ECHOGRAPHY; EXPERIENCE; FOLLOW UP; GLUCOSE METABOLISM; HUMAN; IMAGING SYSTEM; ISOTOPE LABELING; MEDICAL LITERATURE; NEUROENDOCRINE TUMOR; NUCLEAR MEDICINE; PATIENT MONITORING; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PROGNOSIS; REVIEW; TREATMENT OUTCOME; TREATMENT PLANNING; TUMOR DIFFERENTIATION; X RAY; ADRENAL TUMOR; CARCINOMA; GASTROINTESTINAL TUMOR; HYPOPHYSIS TUMOR; LUNG TUMOR; PANCREAS TUMOR; SCINTISCANNING; SIPPLE SYNDROME; THYROID TUMOR;

ADRENAL GLAND NEOPLASMS; CARCINOMA, NEUROENDOCRINE; GASTROINTESTINAL NEOPLASMS; HUMANS; LUNG NEOPLASMS; MULTIPLE ENDOCRINE NEOPLASIA TYPE 2A; PANCREATIC NEOPLASMS; PITUITARY NEOPLASMS; RADIOPHARMACEUTICALS; THYROID NEOPLASMS;

EID: 4544356397     PISSN: 18244785     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (127)

1. Seregni E, Chiti A, Bombardieri E. Radionuclide imaging of neuroendocrine tumors: biological basis and diagnostic results. Eur J Nucl Med 1998;25:639-58.
2. Öberg K. State of the art and future prospects in the management of tumors. Q J Nucl Med 2000;44:3-12.
3. Solcia E, Fiocca R, Rindi G, Villani L, Cornaggia, M, Capella C. The pathology of the gastrointestinal endocrine system. Endocrinol Metab Clin North Am 1993;22:795-821.
4. Solcia E, Klöppel G, Sobin LH. Histological typing of endocrine tumors. 2nd ed. Berlin, Heidelberg: Springer-Verlag; 2000.
5. Percopo V, Kaplan EL. GEP and multiple neuroendocrine tumors. Padova: Piccin; 1996.
6. Modlin IM, Tang LH. Approaches to the diagnosis of gut neuroendocrine tumors: the last word (today). Gastroenterology 1997; 112:583-90.
7. Wiedenmann B, Jensen RT, Mignon M, Medlin CI, Skogseid B, Doherty G et al. Preoperative diagnosis and surgical management of neuroendocrine gastroenteropancreatic tumors: general recommendations by a Consensus Workshop. World J Surg 1998;22: 309-18.
8. Skogseid B. Multiple endocrine neoplasia type I. Clinical genetics and diagnosis. In: Arnold A, editor. Endocrine neoplasms. Norwell: Kluwer Academic Publisher; 1997.p.383-406.
9. Cooper HS. International neoplasms. In: Sternberg SS, editors. Diagnostic surgical pathology. 3rd ed. Philapdelphia, PA: Lippincott, Williams & Wilkins; 1999.p.1413-68.
10. Seregni E, Ferrrari L, Stivanello M, Dogliotti L. Laboratory tests for neuroendocrine tumors Q J Nucl Med 2000;44:22-41.
11. Shapiro B, Fig LM, Gross MD, Shulkin BL, Sisson JC. Neuroendocrine tumors. In: Aktolun C, Tauxe WN, editors. Nuclear oncology. Berlin: Springer; 1999.p.1-31.
12. 18F dopa PET for detection of gastrointestinal carcinoid tumors. Radiology 2001;22:373-80.
13. Eriksson B, Bergstrom M, Sundin A, Juhlin C, Orlefors H, Oberg K et al. The role of PET in localization of neuroendocrine and adrenocortical tumors. Ann N Y Acad Sci 2002;970:15-169.
14. 111In-pentetreotide scintigraphy. J Nucl Med 2002;43:889-95.
15. Colombo P, Paganelli G, Magnani P, Songini C, Fazio F, Faglia G. Immunoscintigraphy with antibodies in patients with endocrine/neuroendocrine tumors. J Endocrinol Invest 1993;16:841-3.
16. 111In-labelled pentetreotide and three-step immuno-scintigraphy with anti-chromogranin A monocloncal antibody in the diagnosis of pituitary adenomas. Cell Biophys 1994;24:307-13.
17. Behr T, Becker W. Metabolic and receptor imaging of metastatic medullary thyroid cancer: does anti-CEA and somatostatin-receptor scintigraphy allow for prognostic predictions? Eur J Nucl Med 1999;26:70-1.
18. Chaudhuri AR, Lewis MK, Bingham JB, Clarke SEM. Registration of MR and SPECT images in medullary thyroid carcinoma. Nucl Med Comm 1993;14:256.
19. 99mTc(V) dimercaptosuccinic acid (DMSA). H Ford Hosp Med J 1989:37:167-8.
20. McEwan AJ, Shapiro B, Sisson JC, Beierwaltes WH, Ackery DM. Radioiodiobenzylguanidine for the scintigraphic location and therapy of adrenergic tumors. Semin Nucl Med 1985;5:132-53.
21. Shulkin BL, Shapiro B, Tobes MC, Shen SW, Wieland DM, Meyers LJ et al. Iodine-123-4-amino-3-iodobenzylguanidine, a new sympatho-adrenal imaging agent: comparison with iodine-131-metaiodobenzylguanidine. J Nucl Med 1986;27:1138-42.
22. 123I-MIBG. Med Pediatr Oncol 1987; 15:170-7.
23. Shulkin B, Shapiro B. Current concepts on the diagnostic use of MIBG in children. J Nucl Med 1998;39:679-88.
24. Patel YC. General aspects of the biology and function of somatostatin. In: Well C, Muller EE, Thorner MO, editors. Basic and clinical aspects of neuroscience. Berlin: Springer: 1992.p.1-16.
25. Patel YC, Amherdt M, Orci L. Quantitative electron micoroscopic autoradiography of insulin, glucagon and somatostatin binding sites on islets. Science 1982;217:1155-6.
26. Krenning EP, Bakker WH, Kooij PP, Breeman WA, Oei HY, de Jong MI. Somatostatin receptor scintigraphy with indium-111-DTPA-D-Phe-1-octreotide in man: metabolism, dosimetry and comparison with iodine-123-tyr-3-octreotide. J Nucl Med 1992;33:652-8.
27. 111In-pentetreotide. J Nucl Med 2001; 42:1134-8.
28. De Jong M, Valkema R, Breeman WAP, Bakker WH, Kooij PPM, Visser TJ et al. Scintigraphy and radionuclide therapy. In: Khalkhali I, Maublant JC, Goldsmith SJ, editors. Nuclear oncology diagnosis and therapy. Philadelphia: Lippincott Williams & Wilkins; 2001.p.373-87.
29. Virgolini I. Peptide imaging. In: Schiepers C, editors. Diagnostic nuclear medicine. Berlin, Heidelberg: Springer-Verlag; 2000.p. 135-58.
30. Virgolini I, Raderer M, Kurtaran A, Angelberg P, Banyai S, Yang Q et al. Vasoactive intestinal peptide (VIP) receptor imaging in the localisation of intestinal adenocarcinomas and endocrine tumors. N Eng J Med 1994;331:1116-21.
31. Virgolini I, Kurtaran A, Raderer M, Leimer M, Angelberg P, Havlik E et al. Vasoactive intestinal peptidereceptor scintigrphy. J Nucl Med 1995;36:1732-9.
32. Ohta H, Yamamoto K, Endo K. A new imaging agent for medullary thyroid cancer. J Nucl Med 1984;323-5.
33. Behr TM, Gratz S, Munz DL, Becker W. Anti-CEA antibodies versus octreotide for the detection of metastatic medullary thyroid cancer: are CEA and somatostatin-receptor expression prognostic factors? In: 44th Annual Meeting of the Society of Nuclear Medicine, San Antonio, Texas, 1997. J Nucl Med 1997;38:9P.
34. Siccardi G, Paganelli G, Pontiroli AE, Pelagi M, Magnani P, Viale G, et al. In vivo imaging of chromogranin A-positive endocrine tumors by three-step monoclonal antibody targeting. Eur J Nucl Med 1996;23:1455-9.
35. Adams S, Baum R, Rink T, Schumm-Drager PM, Usadel KH, Hor G. Limited value of fluorine-18 fluorodeoxyglucose PET for the imaging of neoroendocrine tumors. Eur J Nucl Med 1998;25:79-83.
36. Eriksson B, Begström M, Örlefors H, Sundin A, Öberg K, Langström B. Use of PET in neuroendocrine tumors. In vivo applications and in vitro. Q J Nucl Med 2000;44:68-76.
37. Anderson CJ, Dehdashti F, Cutler PD, Schwarz SW, Laforest R, Bass LA et al. 64Cu-TETA-octreotide as a PET imaging agent for patients with neuroendocrine tumors. J Nucl Med 2001:42: 213-21.
38. Örlefors H, Sundin A, Lilja A, Begström M, Ahlström H, Langström B. Positron emission tomography (PET) with 5-hydroxytryptophan (5-HTP) in the diagnosis and treatment follow-up of carcinoid tumors. J Clin Oncol 1998;7:2534-41.
39. Bombardieri E, Maccauro M, Castellani MR, Chiti A, Procopio G, Bajetta E et al. Radioisotopic imaging of neuroendocrine tumors. Which radiopharmaceutical and which diagnostic procedure? Minerva Endocrinol 2001;26:197-213.
40. Bombardieri E, Maccauro M, De Deckere E, Savelli G, Chiti A. Nuclear medicine imaging of neuroendocrine tumors. Ann Oncol 2001;12:S51-61.
41. Schillaci O, Scopinaro F, Angeletti S, Tavolaro R, Danieli R, Annibale B et al. SPECT improves accuracy of somatostatin receptors scintigraphy in abdominal carcinoids tumors. J Nucl Med 1996;37: 1452-6.
42. 111In-DTPA-pentetreotide scintigraphy in accurate diagnosis of neuroendocrine gastroenteropancreatic tumors. J Hepatobiliary Pancreat Surg 2001;8:473-8.
43. Warner RR, O'dorisio TM. Radiolabeled peptides in diagnosis and tumor imaging: clinical overview. Semin Nucl Med 2002;32: 79-83.
44. Briganti V, Matteini M, Ferri P, Vaggelli L, Castagnoli A, Pieroni C. Octreoscan SPET evaluation in the diagnosis of pancreas neuroendocrine tumors. Cancer Biother Radiopharm 2001;16:515-24.
45. de Herder WW, Lamberts SW. Somatostatin and aomnatostatin analogues: diagnostic and therapeutic uses. Curr Opin Oncol 2002;14:53-7.
46. Lamberts SWJ, Hofland LJ, van Koetsveld PM. Parallel in vivo and in vitro detection of functional somatostatin receptors in human endocrine pancreatic tumors. Consequnces with regard to diagnosis, localisation and therapy. J Clin Endocr Metab 1990;71: 566-74.
47. Kwekkeboom DJ, Krenning EP, Oei HY, Eyck Chj van, Lamberts SWJ. Use of radiolabeled somatostatin to localize islet cell tumors. In: Mignon M, Jensen RT, editors. Frontiers of gastro-intestinal research, vol 23. Endocrine tumors of the pancreas. New York: Kager; 1995.p.298-308.
48. Chiti A, Fanti S, Savelli G, Romeo A, Bellanova B, Rodari M et al. Comparison of somatostatin receptor imaging, computed tomography and ultrasound in the clinical management of neuroendocrine gastro-entero-pancreatic tumors. Eur J Nucl Med 1998;25: 1396-403.
49. Chiti A, Briganti V, Fanti S, Monetti N, Masi R, Bombardieri E. Results and potential of somatostatin receptor imaging in gastroenteropancreatic tract tumors. Q J Nucl Med 2000;44:42-9.
50. Lebtahi R, Cardiot G, Sarda L, Daou D, Faraggi M, Petegnief Y et al. Clinical impact of somatostatin receptor scintigraphy in the management of patients with neuroendocrine gastroenteropancreatic tumors. J Nucl Med 1997;38:853-8.
51. Kaltsas GA, Mukherjee JJ, Grossman AB. The value of radiolabelled MIBG and octreotide in the diagnosis and management of neuroendocrine tumors. Ann Oncol 2001:12:S47-50.
52. Bombardieri E, Crippa F. The increasing impact of PET in the diagnostic work-up of cancer patients. In: Freeman LM, editor. Nuclear medicine annual. Philadelphia: Lippincott Williams & Wilkins; 2002.p.75-121.
53. Pasquali C, Rubello D, Sperti C, Casparoni P, Liessi G, Chierichetti F. Neuroendocrine tumor imaging: can FDG PET detect tumors with poor prognosis and agressive behaviour? World J Surg 1998;22: 588-92.
54. Belhocine T, Foidart J, Rigo P, Najjar F, Thiry A, Quatresooz P et al. Fluorodeoxyglucose positron emission tomography and somatostatin receptor scintigraphy for diagnosing and staging carcinoid tumors: correlations with the pathological indexes p53 and Kii67. Nucl Med Commun 2002;23:727-34.
55. 110mIn-DTPA-D-Phel-octreotide for imaging of neuroendocrine tumors with PET. J Nucl Med 2002;43:1391-7.
56. Hoefnagel CA. Mataiodobenzylguanidine and somatostatin in oncology: role in the management of neural crest tumors. Eur J Nucl Med 1994;25:235-50.
57. Fischer M, Wetter M, Winterberg B, Hengstmann J, Zidek W, Friemann J et al. Scintigraphy localization of pheochromocytomas. Clin Endocr 1948:20:1-7.
58. Jakubowski W, Feltynowsky T, Januszewicz W, Graban W, Leowska L, Pacho R. 131-metaiodobenzylguanidine in localization and treatment of pheochromocytoma. Nucl Med Commun 1985;6:586.
59. Troncone L, Ruffini V, Montemaggi P, Danza FM, Lasorella A, Mastrangelo R. The diagnostic and therapeutic utility of radioionated metaiodobenzylguanidine (MIBG): 5 years of experience. Eur J Nucl Med 1990;16:325-35.
60. Welchik MG, Alavi A, Kressel HY, Engelman K. Localization of pheochromocytoma: MIBG, CT, and MRI correlation. J Nucl Med 1989;30:328-36.
61. Warren MG, Shepstone BJ, Soper N. Iodine-131-metaiodobenzyl-guanidine (131-I-MIBG) for the location of suspected pheochromocytoma. Nucl Med Commun 1989;10:467-75.
62. Maurea S, Cuocolo A, Reynolds JC, Tumeth SS, Begley MG. Iodine-131-metaiodobenzylguanidine scintigraphy in preoperative an postoperative evaluation of paragangliomas:comparison with CT and MRI. J Nucl Med 1993;34:173-9.
63. Tanenbaum F, Lumbroso J, Schlumberger M, Mure A, Plouin PF, Caillou B et al. Comparison of radiolabeled octreotide and metaiodobenzylguanidine (MIBG) scintigraphy in malignant pheochromocytoma. J Nucl Med 1995;36:1-6.
64. Hoefnagel CA, de Kraker J. Childhood neoplasia. In: Murray IPC, Ell PJ, editors. Nuclear medicine in clinical diagnosis and teatment, 2nd ed. London: Churchill Livingstone; 1998:p. 1001-4.
65. 123I-Try-3-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 1993; 20: 716-31.
66. Muscholt TJ, Musholt PB, Dehdashti F, Moley JF. Evaluation of fluorodeoxyglucose-positron emission tomography scanning and its association with glucose transporter expression medullary thyroid carcinoma and pheochromocytoma: a clinically and molecular study. Surgery 1997;122:1049-61.
67. Shulkin BL, Thompson NW, Shapiro B, Francis IR, Sisson JC. Pheochromocytomas: imaging with 2-fluoro-18fluoro-2-deoxy-glucose PET. Radiology 1999;212:35-41.
68. 6-18F-fluorodopamine positron emission tomography (PET) scanning for diagnostic localization of pheochromocytoma. Hypertension 2001;38:6-8.
69. Pacak K, Eisenhofer G, Carrasquillo JA, Chen CC, Whatley M, Goldstein DS. Diagnostic localization of pheochromocytoma: the coming of age of positron emission tomography. Ann N Y Acad Sci 2002;970:170-6.
70. 18F DOPA whole body PET-initial results. Radiology 2002;222:507-12.
71. Kwekkeboom DJ, Krenning EP. Somatostatin receptor imaging in oncology. In: Aktolun C, Tauxe WN, editors. Nuclear oncology, Berlin: Springer; 1999.p.545-57.
72. Telischi FF, Bustillo A, Whitemann ML, Serafini AN, Reisberg MJ, Gomez-Marin O et al. Octreotide scintigrapgy for detection of paragangliomas. Otolaryngol Head Neck Surg 2000;123:358-62.
73. 123I-MIBG scintigrahy in the diagnosis and location of chemodectoma. Nucl Med Comm 1998;19:735-42.
74. Telischi FF, Bustillo A, Whiteman ML, Serafini AN, Reisberg MJ, Gomez-Marin O et al. Octreotide scintigraphy for the detection of paraganglioma. Otolaryngol Head Neck Surg 2000; 122: 358-62.
75. Le Rest C, Bomanji JB, Costa DC, Townsend CE, Visvikis D, Ell PJ. Functional imaging of malignant paragangliomas and carcinoid tumors. Eur J Nucl Med 2001;28:478-82.
76. Wittekindt C, Jungehulsing M, Theissen P, Brochhagen HG. FDG PET imaging of malignant paraganglioma of the neck. Ann Otol Rhinol Laryngol 1999;108:909-12.
77. 123I-vasoactive intestinal peptide (VIP) in the localization and diagnosis of medullary thyroid carcinoma. Nucl Med Biol 1996:23:886-92.
78. Eising EG, Farahati J, Bier D, Knust EJ, Reiners C. Somatostatin receptor scintigraphy in medullary thyroid carcinomas, GEP and carcinoid tumors. Nuklearmedizin 1995:34:1-7.
79. Behr TM, Gratz S, Markus PM, Dunn RM, Hufner M, Schauer A et al. Anti-carcinoembryonic antigen antibodies versus somatostatin analogs in the detection of metastatic medullary thyroid carcinoma: are carcinoembryonic antigen and somatostatin receptor expression prognosis factors? Cancer 1997:80(12 Suppl): 2436-57.
80. Baudin E, Lumbroso J, Schlumberger M, Leclere J, Giammarile F, Gardet P et al. Comparison of octreotide scintigraphy and conventional imaging in medullary thyroid carcinoma. J Nucl Med 1996;37:912-6.
81. 99mTc-MIBI imaging in the follow-up of patients with medullary carcinoma of the thyroid. Eur J Nucl Med 1996;23:1367-71.
82. Kaltas G, Korbonits M, Heintz E, Mukherjee JJ, Jenkis PJ, Chew SL et al. Comparison of somatostatin analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advanced tumors. J Clin Endoc Metabol 2001;86:895-902.
83. Adams S, Baum RP, Hertel A, Schumm-Draeger PM, Usadel KH, Hor G. Comparison of metabolic and receptor imaging in recurrent medullary thyroid carcinoma with histopathological findings. Eur J Nucl Med 1998;25:1277-83.
84. 18F_FDG PET detection of lymph node metastases in medullary thyroid carcinoma. J Nucl Med 2002;43:66-71.
85. Diehl M, Risse JH, Brandt-Mainz K, Dietlein M, Bohuslavizki KH, Matheja P et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in medullary thyroid cancer: results of a multicentre study. Eur J Nucl Med 2001;28:1671-6.
86. Brandt-Mainz K, Muller SP, Gorges R, Saller B, Bockisch A. The value of fluorine-18 fluorodeoxyglucose PET in patients with medullary thyroid cancer. Eur J Nucl Med 2000;27:490-6.
87. Gasparoni P, Rubello D, Ferlin G. Potential role of fluorine-18-deoxyglucose (FDG) positron emission tomography (PET) in the staging of primitive and recurrent medullary thyroid carcinoma. J Endocrinol Invest 1997;20:527-30.
88. 18F-DOPA positron emission tomography for tumor detection in patients with medullary carcinoma and elevated calcitonin levels. Eur J Nucl Med 2001;28:64-71.
89. O'Byrne KJ, Halmos G, Pinski J, Groot K, Szepeshazi K, Schally AV et al. Somatostatin receptor expression in lung cancer. Eur J Cancer 1994;30:1682-7.
90. Reisenger I, Bohuslavitzki KH, Brenner W, Braune S, Dittrich I, Geide A et al. Somatostatin receptor scintigraphy in small-cell lung cancer: results of a multicenter study. J Nucl Med 1998;39:224-7.
91. 111In-DTPA octreotide scintigraphy. Eur J Cancer 1995;31A:184-8.
92. Hoefer M, Schmidt S, Welter J, Kirsch CM, Ukena D, Sybrecht GW. Diagnostic value of somatostin receptor scintigraphy with indium-111 pentetreotide in small-cell bronchial carcinoma. Pneumologie 1998;52:106-12.
93. O'Byrne KJ, Schally AV, Thomas A, Carney DN, Steward WP. Somatostin, its receptor and analogs, in lung cancer. Chemotherapy 2001;47:78-108.
94. Toloza EM, Harpole L, McCrory DC. Noninvasive staging of non-small cell lung cancer: a review of the current evidence. Chest 2003;123:137S-46.
95. Hany TF, Steinert HC, Goerres GW, Buck A, von Schulthess GK. PET diagnostic accuracy: improvement with in-line PET-CT system: initial results. Radiology 2002;225:575-81.
96. 18F 2-deoxyglucose positron emission tomography in primary staging small cell lung cancer. Anticancer Res 2002;22:1257-64.
97. 18F-FDG-PET imaging in small cell lung cancer. Eur J Nucl Med Mol Imaging 2003;30:78-84.
98. 18F-fluorodeoxyglucose positron emission tomography in small-cell lung cancer. Semin Nucl Med 2002;32:272-5.
99. Olshan AF, Bunin GR. Epidemiology of neuroblastoma. In: Brodeur GM, Sawada T, Tsuchida Y, Voute PA, editors. Neuroblastoma. Amsterdam: Elsevier Sciences; 2000.p.33-39.
100. Sisson JC. Radiopharmaceuticals for nuclear endocrinology at the University of Michigan. Cancer Biother Radiopharm 2000;15:305-18.
101. Staalman CR, Heofnagel CA. Imaging of neuroblastoma and metastasis. In: Brodeur GM, Sawada T, Tsuchida Y, Voute PA editors, Neuroblastoma. Amsterdam: Elsevier Sciences; 2000:p.303-32.
102. Maurea S. Lastoria S, Caracò C, Indolfi P, Casale F, di Tullio MT. Iodine-131-MIBG imaging to monitor chemotherapy response in advanced neuroblastoma: comparison with laboratory analysis. J Nucl Med 1994;35:1429-35.
103. Hoefnagel CA, Lewington VJ. MIBG therapy. In: Murray IPC, Ell PJ, editors. Nuclear medicine in clinical diagnosis and treatment, 2nd ed. London: Churchill Livingstone; 1998.p.1067-82.
104. 123I-metaiodobenzylguanidine (MIBG) scintigraphy for the staging of neuroblastoma. Kaku Igaku 1998;35:835-42.
105. Rufini V, Fisher GA, Shulkin BL, Sisson JC, Shapiro B. Iodine-123-MIBG imaging of neuroblastoma: utility of SPECT and delayed J Nucl Med 1996;37:1464-8.
106. Moertel CL, Reubi JC, Scheithauer BS, Schaid DJ, Kvols LK. Expression of somatostatin receptor in childhood neuroblastoma. Am J Clin Pathol 1994;102:752-6.
107. Kropp J, Hofmann M, Bihl H. Comparison of MIBG and pentetreotide scintigraphy in children with neuroblastoma. Is the expression of somatostatin receptors a prognostic factor? Anticancer Res 1997;17:1583-8.
108. Shulkin BL, Hutchinson RJ, Castle VP, Yanik GA, Shapiro B, Sisson JC. Neuroblastoma: positron emission tomography with 2-[flurine-18]-fluoro-2-deoxy-D-glucose compared with metaiodobenzylguanidine scintigraphy. Radiology 1996;199:743-50.
109. Kushner BH, Yeung HW, Larson SM, Kramer K, Cheung NK. Extending positron emission tomography scan utility to high risk neuroblastoma: fluorine-18 fluorodeoxyglucose positron emission tomography as sole imaging modality in follow-up of patients. J Clin Oncol 2001;19:3397-405.
110. Reubi JC, Landolt AM. The growth hormone responses to octreotide is acromegaly correlate with adenoma somatostatin receptor status. J Clin Endocri Metab 1989;68:844-50.
111. Duet M, Mundler O, Ajzenberg C. Somatostin receptor imaging in non-functioning pituitary adenomas: value of an uptake index. Eur J Nucl Med 1994;21:647-50.
112. van Royen EA, Verhoeff NP, Meylaerts SA, Miedema AR. Indium-111-DTPA-octreotide uptake measured in normal and abnormal pituitary glands. J Nucl Med 1996;37:1449-51.
113. 111In-penteotride scintigraphy and calculation of a pituitary uptake index. Nuklearmedicine 1997;36:117-24.
114. Losa M, Magnani P, Mortini P, Persani L, Acerno S, Giugni E et al. Indium-111 pentetreotride single emission tomography in patients with TSH-secreting pituitary adenomas: correlation with the effect of a single administration of octreotide on serum TSH levels. Eur J Nucl Med 1997;24:728-31.
115. de Herder WW, Reijs AE, de Swart J, Kaandorp Y, Lamberts SW, Krenning EP et al. Comparison of iodine-123 epidepride and iodine-123 IBZM for dopamine D2 receptor imaging in clinically non-functioning pituitary macroadenomas and macroprolactinomas. Eur J Nucl Med 1999;26:46-50.
116. Schmidt M, Jockenhovel F, Theissen P, Dietlein M, Krone W, Schicha H. Assessment of endocrine disorders of the lypothalamic-pituitary axis by nuclear medicine techniques. Nuklearmedizin 2002:41:80-90.
117. Adams S, Baum R, Hertel A, Wenisch HJC, Staib-Sebler E, Herrmann G et al. Intraoperativa gamma probe detection of neuroendocrine tumors. J Nucl Med 1998;39:1155-60.
118. Waddington WA, Kettle AG, Heddle RM, Coakley AJ. Intraoperative localization of recurrent medullary carcinoma of the thyroid using indium-111 pentetreotide and a nuclear surgical probe. Eur J Nucl Med 1994;21:363-4.
119. Martelli H, Ricard M, Larroquet M, Wieland M, Paraf F, Fabre M et al. Intraoperative localization of neuroblastoma in children with 123-I or 125-I radioabeled metaiodobenzylguanidine. Surgery 1998;123:51-7.
120. Heij HA, Rutgers EJTH, de Kraker J, Vos A. Intraoperative search for neuroblastoma by MIBG and radioguided surgery with the gamma detector. Med Pediatr Oncol 1997;28:171-4.
121. Ohrvall U, Westlin JE, Kjellberg F, Nilsson S, Juhlin C, Rastad J et al. A gamma detector probe with ex vivo of detection of carcinoid tumors superior to intraoperative palpation. Cancer 1997;80:2495-500.
122. Cirillo F, Bottini A, Lima G, Alquati P. Radioguided surgery in the treatment of gastro-entero-pancreatic neuroendocrine tumors. Minerva Chir 2000;55:517-21.
123. Dietlein M, Knapp WH, Lauterbach KW, Schicha H. Economic evaluation studies in nuclear medicine: the need for standardization. Eur J Nucl Med 1999;26:663-80.
124. Woodward RS, Schnitzler MA, Kvols LK. Reduced uncertainty as a diagnostic benefit: an initial assessment somatostatin receptor scintigraphy's value in detecting distant metastases of carcinoid liver tumors. Healt Econ 1998;7:149-60.
125. Termanini B, Gibril F, Reynolds JC, Doppman JL, Chen CC, Stewart CA et al. Value of somatostatin receptor scintigraphy: a prospective study gastrinoma of its effect on clinical management. Gastroenterology 1997;112:335-47.
126. Kwekkeboom DJ, Lamberts SWJ, Habbena JD, Krenning EP. Cost-effectiveness analysis of somatostatin receptor scintigraphy. J Nucl Med 1996;37:886-92.
127. Oberg K. The ultimate biochemical diagnosis of gastro-entero-pancreatic tumors. Digestion 1996;57:45-7.